UK Markets close in 3 hrs 26 mins
  • FTSE 100

    -88.64 (-1.17%)
  • FTSE 250

    -397.97 (-1.75%)
  • AIM

    -18.05 (-1.56%)

    -0.0057 (-0.48%)

    -0.0034 (-0.2496%)

    -2,984.35 (-9.59%)
  • CMC Crypto 200

    -96.90 (-9.74%)
  • S&P 500

    -50.03 (-1.10%)
  • DOW

    -313.21 (-0.89%)

    -1.39 (-1.62%)

    -8.00 (-0.43%)
  • NIKKEI 225

    -250.64 (-0.90%)

    +13.20 (+0.05%)
  • DAX

    -320.29 (-2.01%)
  • CAC 40

    -128.86 (-1.79%)

Arix Bioscience PLC: Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • ARIX.L

Arix Bioscience PLC (ARIX)
22-Dec-2021 / 11:05 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Arix Bioscience co-leads $31 million Series A financing for new portfolio company Sorriso Pharmaceuticals


LONDON, UK, 22 December 2021: Arix Bioscience plc ("Arix" or "the Company"), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it has co-led a Series A financing in new portfolio company, Sorriso Pharmaceuticals, alongside New Enterprise Associates, Inc. As part of the financing, Arix has committed $13 million (£9.8 million) for a 26% stake on a fully diluted basis. Mark Chin, Managing Director of Arix, will join the Sorriso Board of Directors.

Sorriso Pharmaceuticals is a biotechnology company advancing a pipeline of disease-modifying antibodies for the treatment of inflammatory disease, including Crohn's disease and ulcerative colitis. The Sorriso platform generates potent antibodies that can be delivered orally and are designed to maintain activity throughout the intestinal system. The lead programme, SOR102, is being developed for the treatment of inflammatory bowel disease ("IBD"). SOR102 simultaneously inhibits TNF and IL-23, two clinically validated drivers of IBD. This unique approach combines the stong clinical impact of antibody therapeutics with the benefits of oral administration, resulting in targeted activity, negligible systemic exposure and minimal immunogenicity.

Sorriso is led by Ciara Kennedy, former CEO of Amplyx Pharmaceuticals, a former portfolio company of Arix until its acquisition by Pfizer in April 2021. The Series A financing will enable Sorriso to advance SOR102 into clinical trials and advance its early stage pipeline through preclinical development.

Mark Chin, Managing Director at Arix, commented:

"The ability to modify the course of disease with orally available biological treatments has huge implications for inflammatory diseases of the gut. In IBD, SOR102 is uniquely positioned as the only orally-administered biologic with dual activity against two IBD disease drivers, both of which are clinically validated and therefore significantly de-risked targets. We are excited  to be supporting a management team with whom we have worked successfully in the past to realise the potential of Sorriso's platfrom in what is our third addition to the Arix portfolio this year."

Ciara Kennedy PhD, Chief Executive Officer of Sorriso Pharmaceuticals, commented:

"We are delighted that Arix has chosen to co-lead Sorriso's Series A financing at this important phase of our journey. Our lead programme represents a step change in the treatment of IBD and raises the possibility of treatment early in the course of the condition, reducing disease progression, improving quality of life and offering significant healthcare benefits. I am looking forward to working with Mark and the Arix team again as we advance our pipeline of innovative therapies through clinical development."



For more information on Arix, please contact:


Arix Bioscience plc

+44 (0)20 7290 1050


Powerscourt Group

Sarah MacLeod, Ibrahim Khalil

+44 (0)20 7250 1446



About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.




Category Code:




LEI Code:


Sequence No.:


EQS News ID:



End of Announcement

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting